Nature Index |

Nature Index 2020 Cancer

This supplement features stories of success and challenges in the hard-fought and expensive race to increase survival rates. But it’s not all good news - improved treatments may still be out of reach in the countries where 70% of global cancer deaths occur.

Features and comment

Scientists are nudging the dial on some types of cancer more than others, but it’s fair to ask whether research is delivering value for money.

Nature Index | | Nature

A description of the terminology and methodology used in this supplement, and a guide to the functionality available free online at natureindex.com.

Nature Index | | Nature

Partner content

Integrating basic and clinical research, a new cancer institute established at Peking University welcomes cross-disciplinary researchers from around the world.

Advertisement Feature |

A stronger and more precise form of radiotherapy is poised to take a leading role in mainstream cancer therapy. It also provides options for those with previously untreatable cancers.

Advertisement Feature |

By integrating cancer research, treatment, prevention, and education, a specialized hospital in Tianjin is fulfilling its commitment to provide patients with the best care and medicine.

Advertisement Feature |

Seoul National University’s preclinical research is rapidly translated into clinical trials, particularly in the field of therapeutic resistance.

Advertisement Feature |

Fundamental and translational research at the China Medical University in Taiwan reveals crucial insights for cancer mechanisms, informing the development of precision medicine.

Advertisement Feature |

Shizuoka Cancer Center and its surrounds are creating an advanced cancer treatment and care hub to maximize quality of life in line with longevity.

Advertisement Feature |

Emerging smart tools are helping prevent disease onset and progression. The medical informatics hub at Nagoya University is training specialists that will drive life-saving developments.

Advertisement Feature |

A conversation with PETER SHIELDS, MD, deputy director at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James)

Advertisement Feature |

The Janssen Pharmaceutical Companies of Johnson & Johnson and the Lung Cancer Initiative at Johnson & Johnson are taking on the world’s most deadly cancer.

Advertisement Feature |

A young laboratory in Shenzhen aspires to be a world-class hub for biomedical and life sciences research to prevent and find effective solutions for major diseases, including cancer.

Advertisement Feature |